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Abstract 
Context: Although open radical cystectomy (ORC) is still the standard approach, 
laparoscopic radical cystectomy (LRC) and robot-assisted radical cystectomy (RARC) have 
gained popularity.  
Objective: To report a systematic literature review and cumulative analysis of perioperative 
outcomes and complications of RARC in comparison with ORC and LRC. 
Evidence acquisition: Medline, Scopus, and Web of Science databases were searched using a 
free-text protocol including the terms robot-assisted radical cystectomy or da Vinci radical 
cystectomy or robot* radical cystectomy. RARC case series and studies comparing RARC 
with either ORC or LRC were collected. Cumulative analysis was conducted. 
Evidence synthesis: The searches retrieved 105 papers. According to the different diversion 
type, overall mean operative time ranged from 360 to 420 min. Similarly, mean blood loss 
ranged from 260 to 480 ml. Mean in-hospital stay was about 9 d for all diversion types, with 
consistently high readmission rates. In series reporting on RARC with either extracorporeal 
or intracorporeal conduit diversion, overall 90-d complication rates were 59% (high-grade 
complication: 15%). In series reporting RARC with intracorporeal continent diversion, the 
overall 30-d complication rate was 45.7% (high-grade complication: 28%). Reported 
mortality rates were IRUDOOGLYHUVLRQW\SHV. Comparing RARC and ORC, cumulative 
analyses demonstrated shorter operative time for ORC, whereas blood loss and in-hospital 
stay were better with RARC (all p values <0.003). Moreover, 90-d complication rates of any-
grade and 90-d grade 3 complication rates were lower for RARC (all p values <0.04), 
whereas high-grade complication and mortality rates were similar.  
Conclusions: RARC can be performed safely with acceptable perioperative outcome, 
although complications are common. Cumulative analyses demonstrated that operative time 
was shorter with ORC, whereas RARC may provide some advantages in terms of blood loss 
and transfusion rates and, more limitedly, for postoperative complication rates over ORC and 
LRC. 
Patient summary: Although open radical cystectomy (RC) is still regarded as a standard 
treatment for muscle-invasive bladder cancer, laparoscopic and robot-assisted RC are 
becoming more popular. Robotic RC can be safely performed with acceptably low risk of 
blood loss, transfusion, and intraoperative complications; however, as for open RC, the risk 
of postoperative complications is high, including a substantial risk of major complication and 
reoperation.  
 
1. Introduction 
Radical cystectomy (RC) with regional lymph node dissection is the standard surgical 
treatment for muscle-invasive and high-risk non±muscle-invasive urothelial carcinoma of the 
bladder [1]. Although open RC (ORC) is still the most commonly adopted surgical approach 
[2], minimally invasive techniques have gained popularity such that laparoscopic RC (LRC) 
and robot-assisted RC (RARC) are routinely performed with promising short- and 
intermediate-term results [3].  
Due to increasing evidence in the field of RARC and in preparation for the Pasadena 
international consensus meeting on best practice in RARC and urinary diversion, we 
performed a systematic literature review of perioperative, functional, and oncologic outcomes 
of RARC in comparison with ORC and LRC. We report the findings of this review with a 
cumulative analysis of perioperative outcomes and postoperative complications.  
2. Evidence acquisition 
The systematic literature search was initially performed in September 2013 using the 
Medline, Scopus, and Web of Science databases. The searches included a free-text protocol 
using the terms robot-assisted radical cystectomy or da Vinci radical cystectomy or robot* 
radical cystectomy in all fields of the records for PubMed and Scopus searches and in the 
Title and Topic fields for the Web of Science search. No limits were applied. A full update of 
the searches was done April 28, 2014.  
Two authors (G.N. and B.Y.) separately reviewed the records to select RARC case series as 
well as studies that compared RARC with ORC and RARC with LRC. Discrepancies were 
resolved by open discussion. Other significant studies cited in the reference lists of the 
selected papers were evaluated, as were studies published after the systematic search.  
All noncomparative studies reporting intraoperative and perioperative data (operative time, 
blood loss, transfusion rate, in-hospital stay, readmission, complication rates), functional data 
(urinary continence, erectile function), and oncologic data (positive surgical margins, lymph 
node yield, disease-free survival, cancer-specific survival, overall survival) of RARC were 
collected. The present review included only studies reporting perioperative outcomes and 
complications.  
Studies reporting partial cystectomy, prostate-sparing cystectomy, salvage cystectomy, 
cystectomy for urachal cancers or benign diseases, single-case reports, or pure laparoscopic 
(or mixed) series; those focusing on RC with laparoendoscopic single-site or natural orifice 
transluminal endoscopic surgery; experimental studies on animal models; congress abstracts; 
review papers; editorials; population-based studies; and book chapters were not included in 
the review. All data retrieved from the selected studies were recorded in an electronic 
database.  
Papers were categorized according to the Oxford Level of Evidence Working Group 2011 
levels of evidence (LOEs) for therapy studies: LOE 1, systematic review of randomized trials 
or n-of-1 trials; LOE 2, randomized trial or observational study with dramatic effect; LOE 3, 
nonrandomized controlled cohort or follow-up study; LOE 4, case series, case±control study, 
or historically controlled study; or LOE 5, mechanism-based reasoning [4]. Papers were 
categorized according to the IDEAL recommendations [5]. Methodological reporting of 
complications was evaluated according to the Martin criteria [6]. The systematic review was 
performed in agreement with the PRISMA statement [7]. 
2.1. Statistical analysis 
Cumulative analysis was conducted using Review Manager v5.2 software designed for 
composing Cochrane Reviews (Cochrane Collaboration, Oxford, UK). Statistical 
heterogeneity was tested using the chi-square test. A p value <0.10 was used to indicate 
heterogeneity. If there was a lack of heterogeneity, fixed-effects models were used for the 
cumulative analysis. Random-effects models were used in cases of heterogeneity. For 
continuous outcomes, the results were expressed as weighted mean differences (WMDs) and 
standard deviations (SDs); for dichotomous variables, results were given as odds ratios (ORs) 
and 95% confidence intervals (CIs). Due to limitations in the Review Manager v5.2 software, 
cumulative analysis of continuous variables was possible only when rough data were 
presented as mean and SD. Authors of the papers were contacted to provide missing data 
whenever necessary. For all statistical analyses, two-sided p < 0.05 was considered 
statistically significant.  
3. Evidence synthesis 
3.1. Quality of the studies and level of evidence 
 The flow of this systematic review of the literature is shown in Figure 1. In total, 70 surgical 
series [8±77] and 23 comparative studies [78±100] reported perioperative outcomes and 
complications of RARC.  
Most of the surgical series were retrospective, single-center studies, with the exception of 
some prospective studies [8,9,29,32,33,48,62,63,67,69,71,73,77] and some multi-institutional 
collaboration papers [19,24,26,30,38,39,43,45,72] (LOE 4). Only three of the comparative 
studies were randomized [78±80] (LOE 2b); all other comparative studies were 
nonrandomized, whether prospective or retrospective (LOE 4).  
3.2. Perioperative outcomes after robot-assisted radical cystectomy  
Table 1 summarizes mean operative time, blood loss, transfusion rate, intraoperative 
complication rate, time to flatus, time to bowel movement, in-hospital stay, and readmission 
rate in the RARC surgical series. 
Once duplicate publications and collaborative studies were excluded, weighted mean 
operative time was 360 min (range: 230±618 min) for RARC with extracorporeal conduit, 
420 min (range: 300±496 min) for RARC with extracorporeal neobladder, 340 min (range: 
292±660 min) for RARC with intracorporeal conduit, and 420 min (range: 420±450 min) for 
RARC with intracorporeal neobladder. Overall mean blood loss was 375 ml (range: 208±763 
ml) for RARC with extracorporeal conduit, 390 ml (range: 167±400 ml) for RARC with 
extracorporeal neobladder, 270 ml (range: 200±1118 ml) for RARC with intracorporeal 
conduit, and 480 ml (range: 225±500 ml) for RARC with intracorporeal neobladder. 
Transfusion rates vary, at 12% for RARC with extracorporeal conduit, 44% for RARC with 
extracorporeal neobladder, 14.7% for RARC with intracorporeal conduit, and 7% for RARC 
with intracorporeal neobladder.  
The intraoperative complication rate was 3% in the series reporting RARC with 
extracorporeal conduit, whereas no intraoperative complications were reported in papers 
evaluating either extracorporeal neobladder or intracorporeal diversions. Sufficient data on 
time to flatus and bowel movements were available only for the series analyzing RARC with 
extracorporeal conduit, demonstrating mean time to flatus of 2.5 d (range: 2.1±3.4 d) and 
mean time to bowel movement of 3.1 d (range: 2.8±4 d).  
Length of stay was 8.7 d (range: 3.3±20.7 d) for RARC with extracorporeal conduit, 8.9 d 
(range: 6.7±9 d) for RARC with extracorporeal neobladder, 8.6 d (range: 4.5±9 d) for RARC 
with intracorporeal conduit, and 8.5 d (range: 8±9 d) for RARC with intracorporeal 
neobladder. Readmission rates were consistently high, ranging from 19% for RARC with 
extracorporeal conduit to 75% in one small study for RARC with intracorporeal neobladder.  
3.3. Perioperative outcomes after robot-assisted radical cystectomy and patient 
characteristics  
Two studies analyzed the impact of patient body mass index (BMI) on perioperative 
outcomes [64,70] (Table 2). Butt et al assessed a cohort of 49 patients receiving RARC and 
extracorporeal ileal conduit at Roswell Park Cancer Institute (Buffalo, NY, USA) and failed 
to demonstrate any major significant difference in perioperative outcomes in patients with 
BMI <25, 25±DQG[70]. More recently, Poch et al reported on 56 consecutive patients 
treated at the same institution with RARC and intracorporeal conduit and demonstrated that 
only blood loss was significantly higher in obese patients [64]. 
3.4. Aspects of surgery influencing perioperative outcomes after robot-assisted radical 
cystectomy  
Table 3 summarizes the studies assessing the effects of particular surgical aspects on 
perioperative outcomes. Five papers evaluated the effect of the number of cases previously 
performed on perioperative outcomes [18,35,65,68,71]. Whereas Pruthi et al failed to 
demonstrate any significant modification of the perioperative outcomes among the first 50 
cases of RARC with extracorporeal diversion [18], Hayn et al found significant 
improvements in both mean time for RARC (from 180 min in the first 50 cases to 136 min in 
the last 64 cases; p < 0.001) and lymph node yield (from 16 nodes in the first 50 cases to 24 
nodes in the last 64 cases; p < 0.001) among the first 164 RARC cases performed with 
extracorporeal urinary diversion [71]. Analyzing their first 60 cases of RARC with 
extracorporeal urinary diversion, Richards et al demonstrated reduction in overall 
complication rates from 70% in the first 20 cases to 30% in the second and third 20 cases (p = 
0.013) [35]. 
With regard to reporting intracorporeal diversion, in a series of 100 cases receiving RARC 
with mainly conduit diversion, Azzouni et al found significant reduction in overall diversion 
time with experience (from 140 min in the first 25 cases to 103 min in the last 25 cases; p = 
0.002) [65]. Finally, in a series of 45 patients treated with RARC and intracorporeal 
neobladder, Schumacher et al demonstrated significant improvement in many aspects, 
including increased adoption of lymph node dissection and reduction in operative time (from 
523 min in the first 15 cases to 434 min in the last 15 cases; p = 0.005), in-hospital stay (from 
22.5 d in the first 15 cases to 9.5 d in the last 15 cases; p = 0.006), and >30-d complication 
rates (from 54% in the first 15 cases to 20% in the last 15 cases; p = 0.005) [68]. 
Hayn et al evaluated the impact of previous experience with robot-assisted radical 
prostatectomy (RARP) on RARC outcome [72]. Specifically, RARP experience was 
stratified into four groups: <50, 51±100, 101±150, and >150 cases. RARC operative time, 
blood loss, and lymph node yield were all significantly associated with prior RARP 
experience (all p values <0.001), with the most experienced RARP surgeons experiencing 
lower blood loss but longer operative time and lower lymph node yield [72].  
Finally, two studies compared perioperative outcomes in RARC with intracorporeal and 
extracorporeal diversion [73,74]. Specifically, Guru et al compared the outcomes of 13 
patients receiving intracorporeal ileal conduit and 13 receiving extracorporeal ileal conduit at 
Roswell Park Cancer Institute and failed to demonstrate any significant difference between 
the two groups [73]. Similarly, Kang et al compared 38 patients receiving RARC with either 
extracorporeal conduit (n = 22) or neobladder (n = 14) and 4 patients receiving RARC with 
intracorporeal diversion (three conduits and one neobladder) and demonstrated shorter 
operative time for extracorporeal diversions [74]. Both studies had low power to draw 
definitive conclusions on the issue.  
3.5. Postoperative complication rates after robot-assisted radical cystectomy  
Table 4 summarizes complication rates in the RARC surgical series stratified by diversion 
type. In series reporting on RARC with extracorporeal conduit diversion, overall 30- and 90-
d complication rates were 44% (range: 26±78%) and 59% (range: 30±77%), respectively. 
Low-grade complications were the most prevalent, at 29.4% (range: 8±62%) and 54% (range: 
15±79%) at 30 d and 90 d, respectively. High-grade complications at 30 d and 90 d were 
present in 11.8% (range: 0±35%) and 15% (range: 4±19%), respectively, including high 
reoperation rates (9.7% at 30 d and 14% at 90 d) and relatively low mortality rates (1.6% at 
30 d and 3% at 90 d). 
With regard to RARC with extracorporeal continent diversion, virtually all studies reported 
the experience of City of Hope Comprehensive Cancer Center (Duarte, CA, USA) with an 
overall 90-d complication rate of up to 77%, including 45% low- and 32% high-grade 
complications. The 90-d mortality rate was as high as 5% [25,55,56,58,59]. 
In series reporting on RARC with intracorporeal conduit diversion, the overall complication 
rates at 30, 30±90, and 90 d were 67% (range: 42±86%), 22% (range: 14±23%), and 59% 
(range: 30±77%), respectively. Low-grade complication rates were 45% (range: 32±50%), 
2% (range: 0±14%), and 66% at 30, 30±90, and 90 d, respectively. High-grade complications 
were present in 24% (range: 0±54%), 20% (range: 0±23%), and 15% at 30, 30±90, and 90 d, 
respectively. Reoperation rates were 39% at 30 d, 19% at 30±90 d, and 25% at 90 d. Reported 
mortality rates were relatively low (0% at 30 d, 1.7% at 30±90 d, and 1.7% at 90 d). 
In series reporting RARC with intracorporeal continent diversion, the overall complication 
rates at 30, 30±90, and 90 d were 45.7% (range: 43±62%), and 30% (range: 12±34%), 
respectively. Low-grade complications were reported in 19% (range: 12±33%) and 13.5% 
(range: 13±15%) at 30 d and 30±90 d, respectively. High-grade complications were present in 
28% (range: 15±33%) and 18% (range: 12±21%) at 30 d and 30±90 d, respectively. 
Reoperation rates were 17% at 30 d, 16% at 30±90 d, and 33% at 90 d. Reported mortality 
rates were relatively low (1% at 30 d, 1.7% at 30±90 d, and 2.7% at 90 d). 
3.6. Patient characteristics and aspects of surgery influencing postoperative complications 
after robot-assisted radical cystectomy  
Table 5 summarizes the studies evaluating the impact of patient characteristics and surgical 
factors on complication rates in RARC series. Two studies analyzed the impact of patient 
BMI on complication rates [64,70]. Both papers failed to identify any significant difference 
in complication rates according to patient BMI. Five papers evaluated the effect of the 
number of cases performed on postoperative complications [18,35,65,68,71,77]. With regard 
to RARC with extracorporeal urinary diversion, Richards et al [35] demonstrated significant 
improvement in 90-d complication rates among the first 60 cases performed, with overall 
complication rates decreasing from 70% in the first 20 cases to 30% in the last 20 [35]. 
Conversely, Hayn et al reported stable 240-d complication rates in a larger series of 164 
patients treated at Roswell Park Cancer Institute [71]. With regard to the series reporting 
intracorporeal conduit diversion, Azzouni et al demonstrated little change in 30- and 90-d 
complication rates among the first 100 cases performed [65]. Conversely, two series from the 
Karolinska Institute (Stockholm, Sweden), mainly reporting on RARC with intracorporeal 
neobladder, showed significant improvements in complication rates at 30 d and 30±90 d 
[68,77]. Finally, two studies compared postoperative complication rates for RARC with 
intracorporeal and extracorporeal diversion [73,74]. Both studies reported overlapping 
complication rates, but small sample size and other methodological limitations prevented any 
definitive conclusions from being drawn.  
Few studies evaluated independent predictors of postoperative complications in a more 
formal way, including multivariable analyses (Table 6). Specifically, with regard to series 
reporting on RARC with mainly extracorporeal conduit diversion, three studies reported on 
predictors of complications [28,39,43] and one reported on predictors of readmission [48]. 
Specifically, Kauffman et al analyzed 79 patients treated at Weill Cornell Medical Center 
(New York, NY, USA) and demonstrated that preoperative creatinine level >1.4 mg/dl (OR: 
4.2; p = 0.038) and intravenous fluids >5000 ml (OR: 4.1; p = 0.025) were predictors of any-
grade complication, whereas patient age of >65 yr (OR: 12.7; p = 0.04), estimated blood loss 
>500 ml (OR: 9.7; p = 0.015), and intravenous fluids >5000 ml (OR: 42.1; p = 0.003) were 
predictors of high-grade complications [28]. In a multicenter series of 279 patients treated at 
four US institutions, Smith et al demonstrated that younger age of <65 yr (OR: 0.4; p = 
0.230) and American Society of Anesthesiologists (ASA) score (p = 0.025) were associated 
with higher risk of complications [39]. In another, larger multi-institutional study involving 
>900 patients from >20 institutions, Johar et al performed sophisticated analyses evaluating 
preoperative and intraoperative predictors of any-grade and high-grade complications. 
Among preoperative variables, age at surgery (OR: 1.34; p < 0.0001); BMI (OR: 1.04; p = 
0.006); and, notably, use of neoadjuvant chemotherapy (OR: 1.71; p = 0.007) were associated 
with any grade of complications, whereas age at surgery (OR: 1.39; p = 0.02), BMI (OR: 
1.04; p = 0.024), use of neoadjuvant chemotherapy (OR: 1.88; p = 0.006), and current 
smoking status (OR: 1.68; p = 0.018) were predictive of high-grade complications. Among 
intraoperative variables, blood transfusion (OR: 1.84; p = 0.006) and conduit diversion (OR: 
1.44; p = 0.036) were predictive of any grade of complications, whereas only blood 
transfusion (OR: 1.94; p = 0.009) was associated with high-grade complications [43]. In the 
same study, predictors of 90-d mortality were also assessed, with age (OR: 1.62; p = 0.018), 
among the preoperative variables, and blood transfusions (OR: 4.20; p = 0.001), among the 
intraoperative variables, as the only independent predictors [43]. Finally, Al-Daghmin et al 
reported on readmission rates and demonstrated 30- and 90-d readmission rates of 15% and 
25%, respectively. Patient BMI (OR: 1.12; p = 0.004) and presence of any grade of 
complications (OR: 0.09; p = 0.03) were predictive of 30-d readmission, whereas male sex 
(OR: 0.41; p = 0.014) and BMI (OR: 1.1; p = 0.004) were predictive of 90-d readmission 
[48]. 
With regard to series reporting on RARC with mainly extracorporeal continent diversion, two 
papers reporting the experience of City of Hope Comprehensive Cancer Center assessed 
predictors [56,58]. In the largest series, reporting on 91 patients receiving orthotopic 
neobladder, 51 receiving Indiana pouch, and 67 receiving ileal conduit, Nazmy et al 
demonstrated that ASA score (OR: 7.39; p = 0.01), preoperative hematocrit (HCT; OR: 0.85; 
p = 0.002), and diversion type (Indiana pouch vs conduit: OR: 6.59; p = 0.002; neobladder vs 
conduit: OR: 4.0; p = 0.007) were associated with complications of any grade at 90 d, 
whereas Charlson comorbidity index (OR: 1.44; p = 0.003), preoperative HCT (OR: 0.88; p = 
0.0009), and diversion type (neobladder vs conduit: OR: 4.9; p = 0.001) were predictive of 
high-grade complications at 90 d [58]. Yuh et al also included intraoperative variables and 
found that operative time (OR: 1.71; p = 0.006) and blood loss (OR: 1.0; p = 0.0003) were 
predictive of complications of any grade at 90 d [56]. 
3.7. Cumulative analysis of studies comparing robot-assisted radical cystectomy with open or 
laparoscopic radical cystectomy 
Table 7 summarizes the comparative studies that report perioperative parameters and 
intraoperative complication rates after ORC, LRC, and RARC. With regard to the 
comparison of RARC and ORC, cumulative analyses showed statistically significant 
differences in terms of rates for operative time (WMD: 83.60; 95% CI, 57.1±110.1; p < 
0.00001 in favor of ORC), blood loss (WMD: í521; 95% CI, í644 WRí399; p < 0.00001 in 
favor of RARC), transfusion (OR: 0.16; 95% CI, 0.1±0.27; p < 0.00001 in favor of RARC), 
and in-hospital stay (WMD: í1.26; 95% CI, í2.08 WRí0.43; p = 0.003 in favor of RARC), 
whereas rates for intraoperative complications (OR: 1.34; 95% CI, 0.37±4.77; p = 0.65) were 
similar for RARC and ORC (Fig. 2). Cumulative analysis of mean time to flatus and mean 
time to bowel movement was not possible. Notably, considering only the few available 
randomized controlled trials (RCTs), operative time (WMD: 74.7; 95% CI, í30.1 to 179.5; p 
= 0.16) and in-hospital stay (WMD: 0.03; 95% CI, í1.37 to 1.44; p = 0.96) were overlapping 
for the two procedures.  
With regard to the comparison of RARC and LRC, cumulative analyses showed statistically 
significant differences in terms of rates for transfusion (OR: 0.19; 95% CI, 0.07±0.53; p = 
0.001 in favor of RARC) (Fig.3). Cumulative analysis of the other variables was not possible. 
Table 8 summarized the comparative studies that report postoperative complication rates after 
ORC, LRC, and RARC. With regard to the comparison of RARC and ORC, cumulative 
analyses showed that rates for any grade of complication at 90 d (OR: 0.44; 95% CI, 0.31±
0.61; p < 0.0001) and for grade 3 complications at 90 d (OR: 0.55; 95% CI, 0.31±0.98; p = 
0.04) were in favor of RARC. In contrast, rates at 30 d for any grade of complication (OR: 
0.77; 95% CI, 0.56±1.4; p = 0.09), for grade 3 complications (OR: 0.70; 95% CI, 0.43±1.13; 
p = 0.14), and for high-grade complications (OR: 0.64; 95% CI, 0.32±1.29; p = 0.21); 30-d 
mortality rates (OR: 0.45; 95% CI, 0.14±1.44; p = 0.18); and rates at 90 d for high-grade 
complications (OR: 0.62; 95% CI, 0.37±1.03; p = 0.06) and mortality (OR: 0.45; 95% CI, 
0.12±1.66; p = 0.23) were similar for RARC and ORC (Fig. 4). 
With regard to the comparison of RARC and LRC, cumulative analyses showed that rates at 
30 d for any grade of complication (OR: 0.18; 95% CI, 0.08±0.38; p < 0.0001) and for grade 
3 complications (OR: 0.35; 95% CI, 0.15±0.82; p = 0.02) were significantly lower with 
RARC (Fig. 5). 
3.8. Discussion 
Following the success of RARP and other robotic procedures, da Vinci technology (Intuitive 
Surgical, Sunnyvale, CA USA) has been applied to RC, and the number of RARCs 
performed is increasing; however, according to the most current data available, <20% of RCs 
are performed robotically in the United States [2]. Our systematic review demonstrated that 
RARC can be performed safely, with acceptable operative time, relatively little blood loss, 
and relatively low transfusion rates. Although the risk of intraoperative complications is low, 
postoperative complications are common, and the rate of readmission is relatively high. Some 
preoperative patient characteristics, including age, BMI, renal function, and comorbidity, 
may be associated with the risk of complications. Our cumulative analyses demonstrated that 
operative time was shorter with ORC, whereas blood loss and transfusion rates were 
significantly lower with RARC than with ORC. Conversely, rates for any-grade and grade 3 
complication at 90 d were slightly lower with RARC than with ORC. Similarly, transfusion 
rates were lower with RARC than with LRC, as were any-grade and grade 3 complication 
rates.  
Perioperative outcomes and complication rates are critical issues for complex procedures 
such as RC. These outcomes have been reported extensively for ORC, including reports using 
standardized Martin criteria. In general, ORC is associated with a high risk of complications 
(>60%), including a considerable risk of high-grade complications (13±40% in large series) 
and mortality (up to 7% in some series) [101±105]. ORC outcomes appear to be associated 
with hospital and surgeon experience and volumes, with several studies demonstrating 
improved performance in high-volume centers by high-volume surgeons [106,107]. Our 
analysis suggests that RARC might provide benefit in terms of reduced blood loss and 
transfusion rates when compared with ORC, whereas operative time is shorter with ORC. 
Conversely, complication rates were mostly similar between RARC and ORC and slightly 
better for RARC in comparisons with LRC. However, many of the perioperative 
complications following RC may come from the reconstructive part of the procedure. 
Because most RARC cases reported had extracorporeal reconstruction, it can be hypothesized 
that this approach mitigated some potential benefit of a totally intracorporeal approach. 
However, intracorporeal diversion (especially orthotopic neobladder) is a very complex 
robotic procedure that is currently performed in very few centers and that has complication 
and readmission rates that appear quite high. 
With regard to predictors of complications, in the most comprehensive report on ORC, 
Shabsigh et al demonstrated that sex, ASA score, and type of urinary diversion were 
associated with any grade of complications, whereas age at surgery, prior abdominal surgery, 
and estimated blood loss were associated with high-grade complications [101]. Moreover, 
Svatek et al suggested a role for BMI as a predictor of both any-grade and high-grade 
complications [104]. Very similar results were identified in our systematic review of the 
literature on RARC, with age, ASA score, Charlson comorbidity index, BMI, and blood 
transfusion among the most common predictors [28,39,43]. Notably, in a large multi-
institutional study involving >900 patients from >20 institutions, Johar et al identified the use 
of neoadjuvant chemotherapy as a predictor for any-grade and major complication rates [43]. 
That finding is not in agreement with the literature on ORC [108] and needs to be 
reconfirmed in larger analyses. 
With regard to the comparison of ORC and RARC, in a population-based analysis of the US 
Nationwide Inpatient Sample, Yu et al reported on >7000 patients receiving ORC and 1100 
treated with RARC in 1050 hospitals from 44 states in the United States. Specifically, the 
authors found that RARC was associated with a lower rate of complications (49% vs 64%), 
reduced perioperative mortality (0% vs 2.5%), and lower parenteral nutrition use (6.4% vs 
13.3%) compared with ORC, whereas blood transfusions and length of stay were similar in 
the two groups [109]. Conversely, in another population-based study evaluating almost 35 
000 patients treated with ORC and 2100 with RARC at 279 hospitals across the United States 
between 2004 and 2010 and included in the Premier Perspective Database, Leow et al failed 
to demonstrate significant differences in 90-d postoperative mortality and major complication 
rates between RARC and ORC, whereas 46% decreased odds of minor complications, mainly 
due to reduced need for blood transfusion and total parenteral nutrition, were demonstrated 
[2]. On the whole, the data for our systematic review reconfirmed a lower risk of blood loss 
and transfusion for RARC compared with ORC and LRC and slightly lower risks of any-
grade and high-grade complications at 90 d with RARC, whereas 30-d complication rates and 
30- and 90-d mortality rates were similar for ORC and RARC. The reasons for such 
discrepancies are not clear but could include the well-known limited accuracy of population-
based studies and differences in baseline characteristics of the patients treated with ORC and 
RARC both in population-based studies and in the comparative studies included in the 
present systematic review. 
Although the conclusions of this systematic review represent the best evidence available in 
the literature, some drawbacks must be considered. The papers included in the present 
systematic review contained only three RCTs [78±80], and only one was adequately powered 
to assess a difference in complications [80]. Unfortunately, at the present time, that paper is 
published as a letter to the editor in the New England Journal of Medicine and reports a 
limited amount of data; a more detailed report of the study is awaited. Moreover, most of the 
other low-quality evidence did not adopt accurate methodology for reporting complications. 
It was almost impossible to evaluate the impact of surgeon ability on the reported results due 
to the fact that advanced analyses of the RARC learning curve are lacking, and most of the 
available studies stratifying patient outcomes according to prior experience with RARP or to 
the number of prior RARC cases performed were small and retrospective. However, two 
studies from the Karolinska Institute suggested a decrease in complication rates with 
increasing surgical experience [68,77]. Finally, our comparative analyses were not adjusted 
for the baseline differences in patient characteristics and surgical experience. Considering 
that most of the studies included were not RCTs, it is likely that major differences were 
present between study arms, and this might account for some of the observed findings. 
4. Conclusions 
RARC can be performed safely with acceptable operative time, little blood loss, and low 
transfusion rates. The risk of intraoperative complications is low, but postoperative 
complications and readmission after discharge are common. Cumulative analyses 
demonstrated that operative time was shorter with ORC, whereas blood loss and transfusion 
rates were significantly lower with RARC than with ORC. Conversely, rates for any-grade 
and grade 3 complications at 90 d were slightly lower with RARC than with ORC. Similarly, 
transfusion rates were lower with RARC than with LRC, as were any-grade and grade 3 
complication rates. The lack of solid, high-quality evidence limits the strength of the data. 
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Figure legends 
 
Fig. 1 ± Flowchart of the systematic review. 
 
Fig. 2 ± Comparison of (a) operative time, (b) blood loss, (c) transfusion rates, (d) 
intraoperative complication rates, and (e) in-hospital stay following robot-assisted 
radical cystectomy or open radical cystectomy.  
CI = confidence interval; M-H = Mantel-Haenszel test; ORC = open radical cystectomy; 
RARC = robot-assisted radical cystectomy; SD = standard deviation; WMD = weighted 
mean difference. 
 
Fig. 3 ± Comparison of transfusion rates following robot-assisted radical cystectomy or 
laparoscopic radical cystectomy.  
CI = confidence interval; LRC = laparoscopic radical cystectomy; M-H = Mantel-
Haenszel test; RARC = robot-assisted radical cystectomy. 
 
Fig. 4 ± Comparison of rates for any grade of complication at (a) 30 d and (b) 90 d, (c) 
grade 3 complications at 30 and 90 d, (d) mortality at 30 and 90 d, and (e) major 
complication at 30 and 90 d following robot-assisted radical cystectomy or open radical 
cystectomy.  
CI = confidence interval; M-H = Mantel-Haenszel test; ORC = open radical cystectomy; 
RARC = robot-assisted radical cystectomy. 
 
Fig. 5 ± Comparison of rates at 30 d for (a) any grade of complication and (b) grade 3 
complications following robot-assisted radical cystectomy or laparoscopic radical 
cystectomy.  
CI = confidence interval; LRC = laparoscopic radical cystectomy; M-H = Mantel-
Haenszel test; RARC = robot-assisted radical cystectomy. 
 
 
Table 1 ± Perioperative outcomes in robot-assisted radical cystectomy series stratified by urinary diversion type 
 
Reference Institution IDEAL 
stage 
Cases Study design Nerve-
sparing 
surgery 
Median/ 
mean 
operative 
time, min 
Median/mean 
blood loss, ml 
Transfusi
on rate, 
% 
Intraoperati
ve 
complication
s, % 
Mean time to 
flatus, d 
Mean time to 
bowel 
movement, d 
In-hospital 
stay, d 
Readmiss
ion rate 
Mainly extracorporeal conduit diversion 
Guru et al, 2007 [8] Roswell Park Cancer 
Institute, Buffalo, NY, 
USA 
1 7 Prospective ± ± 335 ± 0 ± ± 8 ± 
Guru et al, 2007 [9] Roswell Park Cancer 
Institute, Buffalo, NY, 
USA 
1 20 Prospective ± 442 555 0 0 ± 4 10 10% 
Mottrie et al, 2007 
[10] 
O.L.V. Clinic, Aalst, 
Belgium 
2a 27 Retrospective 29% 340 301 7 ± ± ± ± ± 
Hemal et al, 2008 
[11] 
All India Institute of 
Medical Sciences, New 
Delhi, India 
1 6 Retrospective ± 330 200 17 0 ± ± 9.2 0 
Lowentritt et al, 2008 
[12] 
Tulane University 
Health Center, New 
Orleans, LA, USA 
2a 4 Retrospective ± 375 338 0 0 ± ± 5 ± 
Murphy et al, 2008 
[13] 
*X\¶V	6W7KRPDV¶
NHS Foundation Trust, 
London, UK 
2a 23 Retrospective 20% 397 278 4 ± ± ± 11.6 ± 
Park et al, 2008 [14] Yonsei University 
College of Medicine, 
Seoul, Korea 
2a 4 Retrospective ± 355 550 ± ± ± ± 12 ± 
Park et al, 2008 [15] Yonsei University 
College of Medicine, 
Seoul, Korea 
2a 11 Retrospective ± 309 615 ± ± ± ± ± ± 
Pruthi et al, 2008 [16] University of North 
Carolina, Chapel Hill, 
NC, USA  
2a 20 Retrospective 85% 366 313 ± 5 2.1 2.8 4.4 ± 
Pruthi et al, 2008 [17] University of North 
Carolina, Chapel Hill, 
NC, USA 
2a 12 
female 
Retrospective 0 276 221 ± ± 1.9 2.4 4.8 ± 
Pruthi et al, 2008 [18] University of North 
Carolina, Chapel Hill, 
NC, USA 
2b 50 Retrospective ± 306 271 ± ± 2 2.6 4.5 ± 
Woods et al, 2008 
[19] 
Multicenter 2b 27 Retrospective ± 499 277 11 ± ± ± ± ± 
Yuh et al, 2008 [20] Roswell Park Cancer 
Institute, Buffalo, NY, 
USA 
2a 54 Retrospective ± ± 557 13 0 ± ± 9.1 ± 
Gamboa et al, 2009 
[21] 
 
University of 
California, 
Irvine, CA, USA 
2a 41 Retrospective ± 498 254 44 7 ± 4 8 ± 
Pruthi et al, 2009 [22] University of North 
Carolina, Chapel Hill, 
NC, USA 
2b 50 Retrospective ± 302 268 ± ± 1.9 2.6 4.5 ± 
Yuh et al, 2009 [23] Roswell Park Cancer 2b 73 Retrospective ± 378 573 ± 1 ± ± 10 ± 
Table
Institute, Buffalo, NY, 
USA 
Hayn et al, 2010 [24] Multicenter 2b 482 Retrospective ± 385 408 ± ± ± ± ± ± 
Josephson et al, 2010 
[25] 
City of Hope 
Comprehensive Cancer 
Center, Duarte, CA, 
USA 
2b 58 Retrospective ± 480 450 38 7 ± ± 10 ± 
Kang et al, 2010 [26] Multicenter 2b 104 Retrospective ± 554 526 ± 4 3.4 ± 18.4 ± 
Kasraeian et al, 2010 
[27] 
Montsouris Institute, 
Paris, France 
2a 9 Retrospective ±  270  400 55 ± ± ± 14 ± 
Kauffman et al, 2010 
[28]  
Weill Cornell Medical 
Center, New York, NY, 
USA 
2b 79 Retrospective ± 360 400 3 0 ± ± 5 ± 
Kwon et al, 2010 [29] Kyungpook National 
University, Daegu, 
Korea 
2a 17 Prospective ± 379 210 35 0 ± ± 20.7 ± 
Martin et al, 2010 
[30] 
Multicenter 2b 59 Retrospective ± ± ± ± ± ± ± ± ± 
Pruthi et al, 2010 [31] University of North 
Carolina, Chapel Hill, 
NC, USA  
2b 100 Retrospective ± 276 250/271 ± 2 2.1 2.8 4.9 11% (30 
d) 
Hayn et al, 2011 [32]  Roswell Park Cancer 
Institute, Buffalo, NY, 
USA 
2b 156 Prospective ± 577 400 16 ± ± ± 8 21%) 
Khan et al, 2011 [33] *X\¶V	6W7KRPDV¶
NHS Foundation Trust, 
London, UK 
2a 50 Prospective ± 361 340 4 4 ± ± 10 18% 
Lavery et al, 2011 
[34] 
Ohio State University, 
Columbus, OH, USA 
2a 15 Retrospective ± 423 160 ± ± ± ± 3.4 13% (30 
d) 
Richards et al, 2011 
[35] 
Wake Forest University 
Baptist Medical Center, 
Winston-Salem, NC, 
USA 
2b 60 Retrospective ± 492 483 ± 3 ± ± 8.1 ± 
Shah et al, 2011 [36] Ohio State University, 
Columbus, OH, USA 
2b 30 Retrospective ± 411 170 3 ± ± ± 3.3 20% 
Lau et al, 2012 [37] 
 
City of Hope 
Comprehensive Cancer 
Center, Duarte, CA, 
USA 
2b 23 aged 
>80 yr 
Retrospective ± 384 300 61 4 ± ± 13 ± 
Mmeje et al, 2013 
[38] 
Multicenter 2b 50 Retrospective ± ± ± ± ± ± ± ± ± 
Smith et al, 2012 [39] Multicenter 2b 227 Retrospective ± 291/327 200/256 ± ± ± ± 5 ± 
Treiyer et al, 2012 
[40] 
University of Saarland, 
Homburg/Saar, 
Germany 
2b 91 Retrospective ± 412 294 ± ± 2.1 2.9 18.8 11% (30 
d) 
Tsui et al, 2012 [41] Chang Gung University 
College of Medicine, 
Taoyuan, Taiwan 
2a 8 Retrospective ± 430 763 63 
(intraopera
tive) 
± ± ± 10.8 ± 
Abbas et al, 2013 
[42] 
Cairo University, Cairo, 
Egypt 
2a 25 Retrospective ± 618 700 40 ± ± ± ± ± 
Johar et al, 2013 [43] Multicenter 2b 939 Retrospective ± ± 580 15 ± ± ± 8 20% 
Khan et al, 2013 [44] *X\¶V	6W7KRPDV
Hospital, London, UK 
1 14 Prospective ± 384 317 7 ± ± ± 12.6 ± 
Marshall et al, 2013 
[45] 
 
Multicenter 2b 765 Retrospective ± 421 479 ± ± ± ± 8 ± 
Saar et al, 2013 [46] University of Saarland, 
Homburg/Saar, 
Germany 
2b 62 Retrospective ± 410 404 ± ± 2.2 2.9 17 13% (30 
d) 
Xylinas et al, 2013 
[47] 
Weill Cornell Medical 
Center, New York, NY, 
USA 
2b 175 Retrospective ± 360 400 17 ± ± ± 7 ± 
Al-Daghmin et al, 
2014 [48] 
Roswell Park Cancer 
Institute, Buffalo, NY, 
USA 
2b 272 Prospective ± 373.9 487 14 ± ± ± ± 25% 
Lin et al, 2014 [49] Taichung Veterans 
General Hospital, 
Taichung, Taiwan 
2b 5 Retrospective ± 230 310 20 ± ± ± ± ± 
Phillips et al, 2014 
[50] 
Boston Medical Center, 
Boston, MA, USA 
2b 23 (aged 
yr) 
Retrospective ± 253 208 30 ± ± ± 8.2 ± 
Snow-Lisy et al, 2014 
[51] 
Cleveland Clinic Lerner 
College of Medicine, 
Cleveland, OH, USA 
2b 17 Retrospective ± ± ± ± ± ± ± ± ± 
Overall* 360 (range: 
230±618) 
375 (range: 
208±763) 
12% 
(range: 0±
63%) 
3% (range: 0±
4%) 
2.5 (range: 
2.1-3.4) 
3.1 (range: 
2.8±4) 
8.7 (range: 
3.3±20.7) 
19% 
(range: 0±
25%) 
Mainly extracorporeal continent diversion 
Menon et al, 2003 [52] Vattikuti Urology 
Institute, Henry Ford 
Hospital, Detroit, MI, 
USA 
1 17 Retrospective ± 300 ± ± ± ± ± ± ± 
Menon et al, 2004 [53] Vattikuti Urology 
Institute, Henry Ford 
Hospital, Detroit, MI, 
USA 
1 3 female Retrospective ± 323 167 ± ± ± ± 6.7 ± 
Manoharan et al, 2011 
[54] 
Miller School of 
Medicine, University 
of Miami, 
Miami, FL, USA 
2a 14 Retrospective ± 360 310 ± 0 ± ± 8.5 ± 
Torrey et al, 2012 [55] City of Hope 
Comprehensive 
Cancer Center, Duarte, 
CA, USA 
2b 34 Retrospective ± 510 504 53 ± ± ± 12.9 39% 
Yuh et al, 2012 [56] City of Hope 
Comprehensive 
Cancer Center, Duarte, 
CA, USA 
2b 196 Retrospective ± 432 400 44 ± ± ± 9 ± 
Pham et al, 2013 [57] Medical College of 
Wisconsin, 
Milwaukee, WI, USA 
2b 11 Retrospective ± 496 315 ± ± ± ± ± ± 
Nazmy et al, 2014 [58] City of Hope 
Comprehensive 
2b 209 Retrospective ± ± ± ± ± ± ±   
Cancer Center, Duarte, 
CA, USA 
Yuh et al, 2014 [59] City of Hope 
Comprehensive 
Cancer Center, Duarte, 
CA, USA 
2b 162 Retrospective ± 438 400 ± ± ± ± ± ± 
Overall* 420 (range: 
300±496) 
390 (range: 
167±400) 
44 0 ± ± 8.9 (range: 
6.7±9) 
39% 
Mainly intracorporeal conduit diversion 
Yohannes et al, 2003 
[60] 
Creighton University, 
Omaha, NE, USA 
1 2 Retrospective 0 660 1118 ± ± ± ± 6 ± 
Pruthi et al, 2010 [61] University of North 
Carolina, Chapel Hill, 
NC, USA 
2a 12 Retrospective ± 318 221 ± 0 2.2 3.2 4.5 17% 
Jonsson et al, 2011 
[62] 
Karolinska Institute, 
Stockholm, Sweden 
2b 9  Prospective ± 460 350 ± ± ± ± 17 ± 
Goh et al, 2012 [63] Keck School of 
Medicine, University 
of Southern California, 
Los Angeles, CA, 
USA 
2a 7 Prospective ± 450 200 71 0 ± ± 9 43% 
Poch et al, 2012 [64] Roswell Park Cancer 
Institute, Buffalo, NY 
2b 56 Retrospective ± 356 338 ± ± ± ± 7.9 29% (30 
d) 
Azzouni et al, 2013 
[65] 
Roswell Park Cancer 
Institute, Buffalo, NY, 
USA 
2b 100 Retrospective ± 352 300 10 ± ± ± 9 16% (30 
d) /20% 
(90 d) 
Bishop et al, 2013 [66] Hertfordshire and 
South Bedfordshire 
Urological Cancer 
Centre, Lister 
Hospital, Stevenage, 
UK 
2a 8 Not reported ± 360 225 25 ± ± ± 9 0 
Collins et al, 2013 [67] Karolinska Institute, 
Stockholm, Sweden 
2b 43  Prospective 16% 292 200 ± ± ± ± 9 ± 
Overall* 340 (range: 
292±660) 
270 (range: 
200±1118) 
14.7% 
(range: 
10±71%) 
0 2.2 3.2 8.6 (range: 
4.5±9) 
19.7% 
(range: 0±
43%) 
Mainly intracorporeal continent diversion 
Jonsson et al, 2011 
[62] 
Karolinska Institute, 
Stockholm, Sweden 
2b 36  Prospective ± 480 625 ± ± ± ± 9 ± 
Schumacher et al, 
2011 [68] 
Karolinska Institute, 
Stockholm, Sweden 
2b 45 Retrospective ± 476 669 ± ± ± ± 9 ± 
Goh et al, 2012 [63] Keck School of 
Medicine, University 
of Southern California, 
Los Angeles, CA, 
USA 
2a 8  Prospective ± 450 225 37 0 ± ± 8 75% 
Collins et al, 2013 [67] Karolinska Institute, 
Stockholm, Sweden 
2b 70  Prospective 70% 420 500 ± ± ± ±  9 ± 
Tyritzis et al, 2013 
[69] 
Karolinska Institute, 
Stockholm, Sweden 
2b 70 Prospective 58% BNS 
8% UNS 
420 500 4 ± ± ± 9 ± 
Overall* 420 (range: 
420±450) 
480 (range: 
225±500) 
7% (range: 
4±37%) 
0 ± ± 8.5 (range: 
8±9) 
75% 
BNS = bilateral nerve sparing; UNS = unilateral nerve sparing. 
* Once duplicate publications from the same centers and multicenter papers were excluded. 
 
Table 2 ± Impact of patient characteristics on perioperative outcomes in robot-assisted radical cystectomy series 
 
Reference Institution IDEAL 
stage 
Cases Study design Intracor
poreal 
urinary 
diversion 
% 
Conduit 
diversion, 
% 
Median/ 
mean 
operative 
time, min 
Median/mean 
blood loss, ml 
Transfusi
on rate, 
% 
Intraoperati
ve 
complication
s, % 
Mean time 
to flatus, d 
Mean time 
to bowel 
movement, 
d 
In-
hospital 
stay, d 
Readmissi
on rate 
Patient BMI 
Butt et al, 2008 [70] Roswell Park Cancer 
Institute, Buffalo, 
NY, USA 
2a BMI <25: 14 Retrospective 0 100 359 630 ± 0 ± ± 11.8 ± 
BMI 25±29: 18 89 366 496 7.7 
%0, 94 371 532 9.1 
Poch et al, 2012 [64] Roswell Park Cancer 
Institute, Buffalo, 
NY, USA 
2b 56 Retrospective 100 100 356 338 ± ± ± ± 7.9 29% (30 d) 
BMI <25 : 14 349 150 7 23% (30 d) 
BMI 25 to 
<30: 21 
380 300 8 33% (30 d) 
%0, 349 500 8.5 32% (30 d) 
BMI = body mass index. 
 
 Table 3 ± Impact of surgical factors on perioperative outcomes in robot-assisted radical cystectomy series 
 
Reference Institution IDEAL 
stage 
Cases Study 
design 
Intracorporea
l urinary 
diversion, % 
Conduit 
diversion, 
% 
Median/ 
mean 
operative 
time, min 
Median/mean 
blood loss, ml 
Transfusi
on rate, 
% 
Intraoperati
ve 
complication
s 
Mean time to 
flatus, d 
Mean time to 
bowel 
movement, d 
In-
hospital 
stay, d 
Readmis
sion rate 
Case volume 
Pruthi et al, 2008 [18] University of North 
Carolina, Chapel 
Hill, NC, USA 
2b 50 Retrospectiv
e 
0 58 306 271 ± ± 2 2.6 4.5 ± 
Cases 1±
10 
70 378 335 2.1 2.8 4.2 
Cases
  11±20 
60 342 330 2.2 3 4.6 
Cases 21±
30 
50 276 245 1.9 2.4 4.6 
Cases 31±
40 
40 270 233 1.7 2.1 4.2 
Cases 41±
50 
70 264 210 1.9 2.6 4.9 
Hayn et al, 2011 [71] Roswell Park Cancer 
Institute, Buffalo, 
NY, USA 
2a Cases 1 ± 
50 
Prospective ± 93 ± 566 ± ± ± ± ± ± 
Cases 51 ± 
100 
631 
Case 101± 
164 
521 
Richards et al, 2011 [35] Wake Forest 
University Baptist 
Medical Center, 
Winston-Salem, NC, 
USA 
2b 60 Retrospectiv
e 
0 92 492 483 ± 3% ± ± 8.1 ± 
Cases 1±
20 
80 524 511 9.2 
Cases 21±
40 
95 503 459 7.8 
Cases 41±
60 
100 449 479 7.4 
Schumacher et al, 2011 
[68] 
Karolinska Institute, 
Stockholm, Sweden 
2b 45 Retrospectiv
e 
100 20 476 669 ± ± ± ± 9 ± 
Cases 1±
15 
33 532 627 12 
Cases 16±
30 
20 462 728 8 
Cases 31±
45 
7 434 654 8 
Azzouni et al, 2013 [65]  Roswell Park Cancer 
Institute, Buffalo, 
NY, USA 
2b 100 Retrospectiv
e 
100 100 352 300 10 ± ± ± 9 16% (30 
d), 20% 
(90 d) 
Cases 1±
25 
366 400 0 7 12% (30 
d), 12% 
(90 d) 
Cases 26±
50 
349 350 12 9 20% (30 
d), 28% 
(90 d) 
Cases 51± 373 300 4 10 20% (30 
75 d), 24% 
(90 d) 
Cases 76±
100 
344 200 24 9 16% (30 
d), 20% 
(90 d) 
Prior RARP experience 
Hayn et al, 2010 [72] Multicenter 2b 482 Retrospectiv
e 
± 75 385 408 ± ± ± ± ± ± 

previous 
RARP: 83 
421 418 
51±100 
previous 
RARP: 
173 
338 286 
101±150 
previous 
RARP: 
168 
401 575 
>150 
previous 
RARP: 48 
444* 188* 
Intracorporeal vs extracorporeal diversion 
Guru et al, 2010 [73] Roswell Park Cancer 
Institute, Buffalo, 
NY, USA 
2a 13 
extracorpo
real ileal 
conduit 
Prospective 0 100 387 454 ± 0 ± ± 8.5 23% 
13 
intracorpo
real ileal 
conduit 
100 391 315 8 8.8 8% 
Kang et al, 2012 [74] Korea University 
School of Medicine, 
Seoul 
2a 22 
extracorpo
real ileal 
conduit 
Retrospectiv
e 
0 100 420 370 ± ± 2.5  ± 14.5 ± 
3 
intracorpo
real ileal 
conduit 
100 510 400 14.2 
Kang et al, 2012 [74] Korea University 
School of Medicine, 
Seoul 
2a 14 
extracorpo
real 
neobladde
r 
Retrospectiv
e 
0 0 496 390 
 
± ± 2.3  ± 16.8 ± 
1 
intracorpo
real 
neobladde
r 
100 545 500 2.5 14 
RARP = robot-assisted radical prostatectomy. 
Table 4 ± Complication rates in robot-assisted radical cystectomy series 
 
Reference Institution IDE
AL 
stage 
Cases Study 
design 
Martin 
criteria 
Follow-up 
duration 
Overall complication 
rate, % 
Complication rate, % 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Mainly extracorporeal conduit diversion 
Guru et al, 2007 [8] Roswell Park Cancer 
Institute, Buffalo, 
NY, USA 
1 7 Prospective 4 ± 14 0 14 0 0 0 
Guru et al, 2007 [9] Roswell Park Cancer 
Institute, Buffalo, 
NY, USA 
1 20 Prospective 4 ± ± ± ± 10 0 5 
Hemal et al, 2008 [11] All India Institute of 
Medical Sciences, 
New Delhi, India 
1 6 Retrospectiv
e 
3 ± ± ± ± 0 
Murphy et al, 2008 
[13] 
*X\¶V	6W7KRPDV¶
NHS Foundation 
Trust, London, UK 
2a 23 Retrospectiv
e 
3 ± 26 4 4 18 ± ± 
Park et al, 2008 [14] Yonsei University 
College of 
Medicine, Seoul, 
Korea 
2a 4 Retrospectiv
e 
± ± ± ± 0 
Pruthi et al, 2008 [16] University of North 
Carolina, Chapel 
Hill, NC, USA 
2a 20 Retrospectiv
e 
5 90 d  30 15 15 ± ± 
Woods et al, 2008 [19] Multi-institutional 2b 27 Retrospectiv
e 
3 ± 33 ± ± 
Gamboa et al, 2009 
[21] 
University of 
California, 
Irvine, CA, USA 
2a 41 Retrospectiv
e 
4 ± 29 17 12 0 
Kauffman et al, 2010 
[28] 
Weill Cornell 
Medical Center, 
New York, NY, 
USA 
2b 79 Retrospectiv
e 
9 30 d 69  58  8 3 0 
90 d 100 37 42 17 4 
Kang et al, 2010 [26] Multicenter 2b 104 Retrospectiv
e 
8 ± 27 19 6 0 2 
Kwon et al, 2010 [29] Kyungpook National 
University, Daegu, 
Korea 
2a 17 Prospective 7 ± 29 29 0 0 0 
Pruthi et al, 2010 [31] University of North 
Carolina, Chapel 
Hill, NC 
2b 100 Retrospectiv
e 
7 30 d  36  28 8 
Hayn et al, 2011 [32] Roswell Park Cancer 
Institute, Buffalo, 
NY, USA 
2b 156 Prospective 10 30 d 40 10 17 11 0 2 
90 d 48 14 21 15 0 2 
Khan et al, 2011 [33] *X\¶V	6W7KRPDV¶
NHS Foundation 
Trust, London, UK 
2a 50 Prospective 8 90 d 34 6 18 10 0 0 
Lau et al, 2012 [37] 
 
City of Hope 
Comprehensive 
2b 23 (aged 
>80 yr) 
Retrospectiv
e 
8 30 d  78 4 58 31 0 4 
Cancer Center, 
Duarte, CA, USA 
Saar et al, 2013 [46] University of 
Saarland, 
Homburg/Saar, 
Germany 
2b 62 Retrospectiv
e 
9 30 d  44 11 
 
23 8 0 2 
Smith et al, 2012 [39] Multicenter 2b 227 Retrospectiv
e 
5 30 d 30  23 7 0 
Treiyer et al, 2012 [40] University of 
Saarland, 
Homburg/Saar, 
Germany 
2b 91 Retrospectiv
e 
6 30 d  49  15  23 7 3 1 
Johar et al, 2013 [43] Multicenter 2b 939 Retrospectiv
e 
9  30 d 41 ± ± ± 1.3 
90 d 48 29 14.8  4.2 
Xylinas et al, 2013 
[47] 
Weill Cornell 
Medical Center, 
New York, NY, 
USA 
2b 175 Retrospectiv
e 
10 30 d 42 8 22 7 3  2 
90 d 45 ± ± ± ± 4 
Al-Daghmin et al, 
2014 [48] 
Roswell Park Cancer 
Institute, Buffalo, 
NY, USA 
2b 272 Prospective 8  30 d ± ± ± 1 
90 d 77 58 14 5 
Phillips et al, 2014 
[50] 
Boston Medical 
Center, Boston, MA, 
USA 
2b 23 (aged 
yr) 
Retrospectiv
e 
7 90 d 35 0 31 4 0 0 
Snow-Lisy et al, 2014 
[51] 
Cleveland Clinic 
Lerner College of 
Medicine, 
Cleveland, OH, 
USA 
2b 17 Retrospectiv
e 
5 ± 53 12 12 17 12 0 
Overall* 30 d Any-grade complication: 
44% (range: 26±78%) 
Low±grade complication: 
 29.4% (range: 8±62%) 
 
High±grade complication: 11.8% (range: 0±
35%) 
Reoperation: 9.7% (range: 0±31%) 
Mortality: 1.6% (range: 0±4%) 
90 d Any-grade complication: 
59% (range: 30±77%) 
Low±grade complication: 54% 
(range: 15±79%) 
 
High±grade complication: 15% (range: 4±
19%) 
Reoperation: 14% (range: 4±17%) 
Mortality: 3% (range: 0±5%) 
Mainly extracorporeal continent diversion 
Josephson et al, 2010 
[25] 
City of Hope 
Comprehensive 
Cancer Center, 
Duarte, CA, USA 
2b 58  Retrospectiv
e 
4 90 d 69 64 3 2 
Kasraeian et al, 2010 
[27] 
Montsouris Institute, 
Paris, France 
2a 9 Retrospectiv
e 
5 ± 33 0 11 22 0 0 
Torrey et al, 2012 [55] City of Hope 
Comprehensive 
Cancer Center, 
Duarte, CA, USA 
2b 34  Retrospectiv
e 
9 90 d  91 16 69 14 0 1 
Yuh et al, 2012 [56] City of Hope 
Comprehensive 
Cancer Center, 
2b 196 Retrospectiv
e 
10 90 d  80 45 31 4 
Duarte, CA, USA 
Nazmy et al, 2014 [58] City of Hope 
Comprehensive 
Cancer Center, 
Duarte, CA, USA 
2b 209 Retrospectiv
e 
10 90 d 77 45 27 5 
Yuh et al, 2014 [59] City of Hope 
Comprehensive 
Cancer Center, 
Duarte, CA, USA 
2b 162 Retrospectiv
e 
8 52 mo 82 45 37 
Mainly intracorporeal conduit diversion 
Pruthi et al, 2010 [61] University of North 
Carolina, Chapel 
Hill, NC, USA 
2a 12 Retrospectiv
e 
5 30 d  42 ± ± ± ± ± 
90 d 58 
Jonsson et al, 2011 
[62] 
Karolinska Institute, 
Stockholm, Sweden 
2b 9  Prospective 8 30 d  44 11 0   22 11 0  
After first 30 d 33 22  0 22 0 0 
Goh et al, 2012 [63] Keck School of 
Medicine, 
University of 
Southern California, 
Los Angeles, CA, 
USA 
2a 7  Prospective 8 30 d  45 45 0 
After first 30 d 14 14 
Azzouni et al, 2013 
[65] 
Roswell Park Cancer 
Institute, Buffalo, 
NY, USA 
2b 100 Retrospectiv
e 
8  30 d 63 50 13 
90 d 81 66 15 
Bishop et al, 2013 [66] Hertfordshire and 
South Bedfordshire 
Urological Cancer 
Centre, Lister 
Hospital, Stevenage, 
UK 
2a 8 Not reported 6 30 d 75 25 25 25 0 0 
Collins et al, 2013 [67] Karolinska Institute, 
Stockholm, Sweden 
2b 43 Prospective 8 30 d  86 9 23 42 12 0 
After first 30 d 23 0 0 19 2 2 
Overall* 30 d  Any-grade 
complication: 67% 
(range: 42±86%) 
Low±grade complication: 45% 
(range: 32±50%) 
 
High±grade complication: 24% (range: 0±
54%) 
Reoperation: 39% (range: 25±42%) 
Mortality: 0%  
30±90 d Any-grade complication: 
22% (range: 14±23%) 
Low±grade complication: 2% 
(range: 0±14%) 
High±grade complication: 20% (range: 0±
23%) 
Reoperation: 19% 
Mortality: 1.7% (range: 0±2%)  
90 d Any-grade complication: 
59% (range: 30±77%) 
Low±grade complication: 66% High±grade complication: 15% 
Reoperation: 25% (range: 14±51%) 
Mortality: 1.7% (range: 0±2%) 
Mainly intracorporeal continent diversion 
Akbulut et al, 2011 
[75] 
Ankara Ataturk 
training and research 
hospital 
2a 12 Not reported 7 30 d  67 25 25 17 0 0 
After first 30 d 41 8 17 8 0 8 
Jonsson et al, 2011 
[62] 
Karolinska Institute, 
Stockholm, Sweden 
2b 36  Prospective 8 30 d  39  14  6  19 0 0 
After first 30 d 33 14 3 16 0 0 
Schumacher et al, 
2011 [68] 
Karolinska Institute, 
Stockholm, Sweden 
2b 45 Retrospectiv
e 
10 30 d   40  13 4 20 2 0 
After first 30 d 31 11 2 18 0 0 
Canda et al, 2012 [76] Ankara Ataturk 
training and research 
hospital 
2a 27 Not reported 6 30 d  48 11 22 11 0 4 
After first 30 d 27 4 11 8 0 4 
Goh et al, 2012 [63] Keck School of 
Medicine, 
University of 
Southern California, 
Los Angeles, CA, 
USA 
2a 8  Prospective 8 30 d  62 37  25 0 
After first 30 d 12 ± 12 0 
Collins et al, 2013 [67] Karolinska Institute, 
Stockholm, Sweden 
2b 70 Prospective 8 30 d  43 4 8 20 11 0 
After first 30 d 34 0 13 19 1 1 
Overall* 30 d Any-grade complication: 
45.7% (range: 43±62%) 
Low±grade complication: 19% 
(range: 12±33%) 
 
High±grade complication: 28% (range: 15±
33%) 
Reoperation: 17% (range: 11±20%) 
Mortality: 1% (range: 0±4%) 
30±90 d Any-grade complication: 
30% (range: 12±34%) 
Low±grade complication: 
13.5% (range: 13±15%) 
High±grade complication: 18% (range: 12±
21%) 
Reoperation :16% (range: 8±19%) 
Mortality: 1.7% (range: 0±4%) 
90 d ± ± Reoperation: 33% (range: 19±39%) 
Mortality: 2.7% (range: 0±8%) 
* Once duplicate publications from the same centers and multicenter papers were excluded. 
Table 5 ± Impact of patients characteristics and surgical factors on complication rates in robot-assisted radical cystectomy series 
 
Reference Institutio
n 
IDEA
L 
stage 
Cases Study 
desig
n 
Intracorporeal 
urinary diversion, 
% 
Conduit 
diversion, % 
Martin 
criteria 
Follow-up 
duration 
Overall complication 
rate, % 
Complication rate, % 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Patients BMI 
Butt et al, 2008 [70] Roswell 
Park 
Cancer 
Institute, 
Buffalo, 
NY, USA 
2a BMI <25: 14 Retros
pectiv
e 
0 100 5 ± 21 ± ± ± ± 0 
BMI 25±29: 
18 
89 33 0 
%0, 94 24 6 
Poch et al, 2012 [64] Roswell 
Park 
Cancer 
Institute, 
Buffalo, 
NY, USA 
2b 56 Retros
pectiv
e 
100 100 5 90 d  57 ± ± ± ± ± 
BMI <25 : 14 43 
BMI 25 to 
<30: 21 
67 
%0, 57 
Case volume 
Hayn et al, 2011 [71] Roswell 
Park 
Cancer 
Institute, 
Buffalo, 
NY, USA 
2a Cases 1±50  Prosp
ective 
± 93 9 240 d 68 26 18 18 0 6 
Cases 51±100 62 14 22 24 0 2 
Case 101±164 62 17 23 21 0 0 
Richards et al, 2011 [35] Wake 
Forest 
Universit
y Baptist 
Medical 
Center, 
Winston-
Salem, 
NC, USA 
2b 60 Retros
pectiv
e 
0 92 6 90 d 43 3 53 33 10 3 
Cases 1±20 80 70* 5 45 5 10 5 
Cases 21±40 95 30* 0 20 10 0 0 
Cases 41±60 100 30* 0 15 10 5 0 
Schumacher et al, 2011 
[68] 
Karolinsk
a 
Institute, 
Stockhol
m, 
Sweden 
2b 45 Retros
pectiv
e 
100 20 10 30 d (>30 d)  40 (31) *  13 (11) 4 (2) 20 (18) 2 (0) 0 
Cases 1±15 33 66 (53) * 27 (7) 7 (7)  27 (40) 7 (0) 
Cases 16±30 20 27 (20) * 13 (7) 7 (0) 7 (14) 0 (0) 
Cases 31±45 7 27 (20) * 0 (20) 0 (0) 27 (0) 0 (0) 
Azzouni et al, 2013 [65] Roswell 
Park 
Cancer 
Institute, 
Buffalo, 
NY, USA 
2b 100 Retros
pectiv
e 
100 100 8 30 d (90 d) 63 (81) 50 (66) 13 (15) 
Cases 1±25 52 (72) 32 (48) 20 (24) 
Cases 26±50 56 (76) 36 (56) 20 (20) 
Cases 51±75 76 (88) 68 (80) 8 (8) 
Cases 76±100 68 (88) 64 (80) 4 (8) 
Collins et al, 2014 [77] Karolinsk
a 
2b Cases 1±10 Prosp
ective 
100 0 6 30 d (>30 d) 70 * (60)* 10 (0) 30 (10) 20 (50) 10 (0) 0 
Cases 11±20 20 * (40)* 10 (0) 0 (10) 0 (20%) 10% 
Institute, 
Stockhol
m, 
Sweden 
(10%) 
Cases 21±30 20 * (20)* 0 (0) 0 (20) 20 (0) 0 (0) 
Cases 31±40 30 * (10)*  0 (0) 0 30 (10) 0 (0) 
Cases 41±47 29 * (29)* 0 (0) 0 (29) 0 (0) 29 (0) 
Intracorporeal vs extracorporeal diversion 
Guru et al, 2010 [73] Roswell 
Park 
Cancer 
Institute, 
Buffalo, 
NY, USA 
2a 13 
intracorporeal 
ileal conduit 
Prosp
ective 
100 100 7 90 d 30 0 15 15 0 0 
13 
extracorporea
l ileal conduit 
0 38 23 15 
Kang et al, 2012 [74] Korea 
Universit
y School 
of 
Medicine, 
Seoul, 
Korea 
2a 38 
extracorporea
l diversion 
Retros
pectiv
e 
0 58 5 90 d 42 21 21 
4 
intracorporeal 
diversion 
100 75 25 25 0 
BMI = body mass index. 
* Statistically significant. 
Table 6 ± Predictors of complication rates in robot-assisted radical cystectomy series 
 
Reference Institution IDEA
L 
stage 
Cases Study 
design 
Martin 
criteria 
Follow-up 
duration 
Overall 
complication 
rate, % 
Predictors of complications 
Mainly extracorporeal conduit diversion 
Kauffman et al, 2010 
[28] 
Weill Cornell 
Medical Center, 
New York, NY, 
USA 
2b 79 Retrospectiv
e 
9 30 d 69 Any-grade complications: creatinine level >1.4 mg/dl, i.v. fluids >5000 ml 
High-grade complications: patients aged >65 yr, EBL >500 ml, and i.v. fluids >5000 ml 90 d 100 
Smith et al, 2012 [39] Multicenter 2b 227 Retrospectiv
e 
5 30 d 30  High-grade complications: aged <65 yr, higher ASA score 
Johar et al, 2013 [43] Multicenter 2b 939 Retrospectiv
e 
9  30 d 41 Any-grade complications: age, BMI, neoadjuvant chemotherapy, receipt of blood 
transfusion, conduit diversion  
High-grade complications: age, BMI, neoadjuvant chemotherapy, current smoking, receipt 
of blood transfusion 
90 d 48 
Al-Daghmin et al, 
2014 [48] 
Roswell Park Cancer 
Institute, Buffalo, 
NY, USA 
2b 272 Prospective 8  30 d ± 30-d readmission: BMI  
90-d readmission: sex and BMI  90 d 77 
Mainly extracorporeal continent diversion 
Yuh et al, 2012 [56] City of Hope 
Comprehensive 
Cancer Center, 
Duarte, CA, USA 
2b 196 Retrospectiv
e 
10 90 d  80 90-d any-grade complications: age, ASA, preop HCT, OR time, EBL, diversion type 
90-d high-grade complications: CCI, preop. HCT, orthotopic diversion 
Nazmy et al, 2014 [58] City of Hope 
Comprehensive 
Cancer Center, 
Duarte, CA, USA 
2b 209 Retrospectiv
e 
10 90 d 77 90-d any-grade complications: ASA, preop HCT, diversion type 
90-d high-grade complications: CCI, HCT, diversion type 
ASA = American Society of Anesthesiologists; BMI = body mass index; CCI = Charlson comorbidity index; EBL = estimated blood loss; HCT = hematocrit; i.v. = intravenous; 
OR = operating room; preop = preoperative. 
  
Table 7 ± Perioperative parameters and intraoperative complication rates after open, laparoscopic, and robot-assisted radical cystectomy 
 
Comparison LOE Reference No. of 
cases 
Median/ 
mean 
operative 
time, min 
Median/mean 
blood loss, ml 
Transfusi
on rate, 
% 
Intraoperative 
complications, % 
Mean time 
to flatus, d 
Mean time to 
bowel 
movement, d 
In-hospital 
stay, d 
RARC vs 
ORC 
2b          
  Nix et al, 2010 [78] 21 RARC 
20 ORC 
252  
211  
258  
575  
± ± 2.3  
3.2  
3.2  
4.3  
5.1  
6.0  
  Parekh et al, 2013 
[79] 
20 RARC 
20 ORC 
308 ± 77 
288 ± 60 
627 ± 554 
1113 ± 935 
 40  
50  
± ± ± 9.2 ± 7.8 
8.9 ± 5.6 
  Bochner et al, 2014 
[80] 
60 RARC 
58 ORC 
456 ± 82 
329 ± 77 
± ± ± ± ± 8 ± 3 
8 ± 5 
 4          
  Rhee et al, 2006 
[81] 
7 RARC 
23 ORC  
638 ± 46 
507 ± 110  
479 ± 551 
1109 ± 398 
57  
87  
± ± ± 11 ± 2 
13 ± 3 
  Galich et al, 2006 
[82] 
13 RARC 
24 ORC 
697 
395 
500 
1250 
54 
75 
± ± ± ± 
  Pruthi et al, 2007 
[83] 
 
20 RARC 
24 ORC 
366  
222  
313  
588  
± 5  
0 
2.1  
2.9  
2.8 
3.8  
4.4 
5.3  
  Ng et al, 2010 [84] 83 RARC 
104 ORC  
375 ± 90 
357 ± 132 
460 ± 299 
1172 ± 916 
± ± ± ± 5.5  
8  
  Richards et al, 
2010 [85] 
35 RARC 
35 ORC  
530  
240  
350  
1000  
17  
71  
± ± ± 7  
8  
  Martin et al, 2011 
[86] 
19 RARC 
14 ORC 
280  
320  
255  
696 
± ± ± ± 5  
10  
  Gondo et al, 2012 
[87] 
11 RARC 
15 ORC 
408.5 ± 
55.886 
363 ± 
111.255 
656.9 ± 452.02 
1788.7 ± 972.13 
0 
40 
9 
0 
± ± 40.2 ± 9.282 
37 ± 9.921 
  Khan et al, 2012 
[88] 
48 RARC 
52 ORC 
386 
320 
337 
1351 
 4 
58 
± ± ± 9.9 
19.2 
  Styn et al, 2012 
[89] 
50 RARC 
100 ORC  
455 ± 100 
349 ± 87  
350  
475 
 4  
24  
± ± ± 9.5 ± 8.8 
10.2 ± 8.4 
  Sung et al, 2012 
[90] 
35 RARC 
104 ORC  
578 ± 153 
501 ± 110 
448.0 ± 231.6 
1063.4 ± 892.7 
11  
57  
1  
0 
± ± 28.9 ± 11.9 
27.1 ± 13.4 
  Anderson et al, 
2013 [91] 
103 
RARC 
375 ORC 
403 ± 93 
281 ± 77 
411 ± 271 
806 ± 660 
± ± ± ± ± 
  Kader et al, 2013 
[92] 
100 
RARC 
100 ORC 
451 
393 
420 
983 
15 
47 
± ± ± 7.8 
12.2 
  Knox et al, 2013 
[93] 
58 RARC 
84 ORC 
468 
396 
276 
1522 
5 
80 
± 4.3 
5.9 
± 6.3 
10.8 
  Maes et al, 2013 
[94] 
14 RARC 
14 ORC 
383  
268  
470  
942  
7  
29  
± ± ± 11.2  
11.4  
  Musch et al, 2014 
[95] 
100 
RARC 
42 ORC 
410 ± 68  
351± 92  
351 ± 170 
810 ± 621 
 27  
60  
3  
5  
± 2.3 ± 1.5 
2.3 ± 1.1 
17.1 ± 7.6 
19.9 ± 12 
  Nepple et al, 2013 
[96]  
36 RARC 
29 ORC 
410  
345  
675  
1497  
39 
83  
± ± ± 7.9  
9.6  
  Trentman et al, 
2013 [97] 
96 RARC 
102 ORC  
372 ± 73 
259 ± 70  
257.7 ± 164.3 
601.8 ± 491.4 
31  
60  
± ± ± 7.1 ± 5.8 
9.8 ± 5 
  Ahdoot et al,2014 
[98] 
51 RARC 
51 ORC 
346 
369 
300 
900 
22 
33 
± ± ± 7 
7 
RARC vs 
LRC 
4          
  Abraham et al, 
2007 [100] 
14 RARC 
20 LRC 
410 
419 
212 
653 
42 
70 
7 
15 
± ± 5.8 ± 0.9 
9.4 ± 7.4 
  Khan et al, 2012 
[88] 
48 RARC 
58 LRC 
386 
316 
337 
480 
4 
26 
± ± ± 9.9 
16 
LOE = level of evidence; LRC = laparoscopic radical cystectomy; ORC = open radical cystectomy; RARC = robot-assisted radical cystectomy. 
Table 8 ± Comparative studies evaluating complication rates after open, laparoscopic, and robot-assisted radical cystectomy 
Comparison LOE Reference No. of 
cases 
Intracorpore
al urinary 
diversion, % 
Conduit 
diversion, % 
Martin 
criteria 
Follow-up Overall 
complication 
rate, % 
Complications rate, % 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
RARC vs 
ORC 
2b Nix et al, 2010 [78] 21 RARC 
20 ORC  
0 66  
70  
3 ±  33  
50  
± ± ± ± ± 
  Parekh et al, 2013 
[79] 
20 RARC  
20 ORC  
0 ± 4 ± ± ± 25 
25 
  Bochner et al, 2014 
[80] 
60 RARC 
58 ORC 
0    ± ± ± 22 
21 
 4           
  Galich et al, 2006 
[82] 
13 RARC 
24 ORC 
0 100 6 ±  15 
17 
± ± ± ± 0 
4 
  Wang et al, 2008 
[99] 
33 RARC  
21 ORC  
0 53  
52  
5 ±  21 
24  
± ± ± 
  Pruthi et al, 2007 
[83] 
 
20 RARC  
24 ORC  
0 50 5 90 d 30  
 33  
± ± ± ± ± 
  Ng et al, 2010 [84] 83 RARC  
104 ORC  
0 57 
49 
10 30 d 
 
41 
59 
12 
7 
19 
22 
8 
19 
1 
6 
0 
5 
90 d 
 
48 
61 
13 
8 
17 
23 
16 
20 
1 
6 
0 
6 
  Richards et al, 
2010 [85] 
35 RARC  
35 ORC  
0 86 6 30 d 60  
66  
 3  
 11  
37  
29  
 
11  
14  
 
6  
11  
 
 3  
 0  
 
  Gondo et al, 2012 
[87] 
11 RARC 
15 ORC 
0 63 
60 
5 30 d 54 
73 
 18 
 40 
 36 
 27  
0 
7 
0 
0 
0 
0 
  Khan et al, 2012 
[88] 
48 RARC 
52 ORC 
0 87 
90 
7 ± 42 
71 
25 
40 
17 
27 
0 
 2 
0 
 2 
  Styn et al, U2012 
[89] 
50 RARC  
100 ORC  
0 72 
72 
8 30 d 
 
66  
62  
72  
79  
28  
21  
  Sung et al, 2012 
[90] 
35 RARC  
104 ORC  
0 37 
82 
8 90 d 63  
74  
26  
 5  
29  
 45  
 6  
16  
0  
4  
3  
3  
  Kader et al, 2013 100 0 97 6 90 d 35 1 25  6  3  1 
[92] RARC 
100 ORC 
83 57  7  30  11  11 0 
  Knox et al, 2013 
[93] 
58 RARC 
84 ORC 
0 91 
89 
8 30 d 24 
58 
 5 
 4 
 12 
 38 
 21 
 14 
 3 
6 
 2 
 2 
90 d 45 
78 
± ± 
>90 d 73 
88 
  Maes et al, 2013 
[94] 
14 RARC  
14 ORC  
0 100 
± 
4 ± 57 
78 
 36 
 64 
 21 
 14  
  Musch et al, 2014 
[95] 
100 
RARC  
42 ORC  
0 76 
± 
10 90 d  
(60 d for ORC) 
59 
93 
35  
51  
24 
43  
RARC vs 
LRC 
4             
  Abraham et al, 
2007 [100] 
14 RARC 
20 LRC 
0 
0 
100 
100 
5 ± 21 
55 
± 
± 
 14 
 35 
 7 
 20 
± 
± 
± 
± 
  Khan et al, 2012 
[88] 
48 RARC 
58 ORC 
0 87 
96 
7 ± 42 
81 
25 
41 
 17 
 36 
0 
0 
0 
 3 
LOE = level of evidence; LRC = laparoscopic radical cystectomy; ORC = open radical cystectomy; RARC = robot-assisted radical cystectomy. 
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